Our Pricing

What Is Mounjaro USK and How to Access It in the UK

Published: 1 October 2026

If you've searched for 'mounjaro usk', you're likely looking for Mounjaro (tirzepatide) weight loss injections available in the UK. Mounjaro is a prescription-only GLP-1 receptor agonist licensed by the MHRA for chronic weight management in adults with a BMI of 30 kg/m² or above, or 27 kg/m² with weight-related health conditions. At Cured Pharmacy, Mounjaro is available from £124.99 following a free online clinical assessment by our UK-registered prescribers, with £20 off your first order using code Weightlossnew.

Understanding Mounjaro USK: What UK Patients Need to Know

Mounjaro USK refers to Mounjaro available in the UK market, a once-weekly injectable medication containing tirzepatide as its active ingredient. Tirzepatide works by activating both GLP-1 and GIP receptors, which regulate appetite, food intake, and blood sugar levels[1]. This dual-action mechanism distinguishes Mounjaro from single-agonist medications like Wegovy (semaglutide), potentially offering enhanced weight loss outcomes for eligible patients.

Clinical trials demonstrated that Mounjaro USK users achieved significant weight reduction when combined with lifestyle interventions. In the SURMOUNT-1 trial, participants taking the highest maintenance dose (15mg) lost an average of 20.9% of their body weight over 72 weeks, compared to 3.1% in the placebo group[2]. These results positioned tirzepatide as one of the most effective pharmacological options for chronic weight management currently licensed in the UK.

Access to Mounjaro USK requires a valid prescription from a UK-registered healthcare professional. At Cured Pharmacy, our clinical team conducts a comprehensive online assessment to determine suitability, reviewing your medical history, current medications, and weight management goals. This ensures safe, appropriate prescribing in line with MHRA and NICE guidelines for obesity treatment.

Mounjaro USK Dosing Schedule and Administration in the UK

The Mounjaro USK dosing protocol follows a gradual escalation schedule designed to minimise gastrointestinal side effects while optimising weight loss outcomes. Treatment typically begins with a 2.5mg subcutaneous injection once weekly for four weeks, serving as an initial tolerability dose rather than a therapeutic maintenance dose[3].

After the first month, your prescriber will increase the dose to 5mg weekly for four weeks, then progress through 7.5mg, 10mg, 12.5mg, and finally 15mg as the maximum maintenance dose. Each increment occurs at four-week intervals, allowing your body to adjust to the medication's effects. Not all patients require the highest dose—your UK prescriber will determine the optimal maintenance dose based on your weight loss response and tolerability.

Mounjaro USK comes in pre-filled KwikPen devices for convenient self-administration. Injections are given subcutaneously in the abdomen, thigh, or upper arm, rotating injection sites each week to reduce the risk of lipodystrophy. Proper injection technique and storage (refrigerated at 2-8°C until first use) are essential for maintaining medication efficacy throughout your treatment journey.

How to Administer Mounjaro USK Injections Safely

Before administering your Mounjaro USK injection, wash your hands thoroughly and inspect the pen to ensure the solution is clear and colourless. Remove the pen from the refrigerator 30 minutes before injection to allow it to reach room temperature, which reduces injection site discomfort. Attach a new needle for each dose, prime the pen according to the manufacturer's instructions, and select your dose as prescribed by your UK clinician. After injecting, hold the pen in place for five seconds to ensure complete dose delivery, then safely dispose of the used needle in a sharps container[4].

Mounjaro USK Side Effects and Safety Considerations for UK Users

Like all GLP-1 receptor agonists, Mounjaro USK can cause side effects, though not everyone experiences them. The most commonly reported adverse effects are gastrointestinal in nature, including nausea, diarrhoea, vomiting, constipation, and abdominal discomfort. These symptoms typically occur during dose escalation and often diminish as your body adjusts to the medication[1].

In clinical trials, approximately 10-20% of participants experienced nausea during the initial weeks of Mounjaro USK treatment, with most cases being mild to moderate in severity[2]. Eating smaller, more frequent meals, avoiding high-fat foods, and staying well-hydrated can help manage these symptoms. If side effects become severe or persistent, contact your prescriber—they may recommend slowing the dose escalation or adjusting your treatment plan.

Serious side effects are rare but require immediate medical attention. These include signs of pancreatitis (severe abdominal pain radiating to the back), symptoms of thyroid tumours (lump in the neck, difficulty swallowing, persistent hoarseness), severe allergic reactions, or signs of gallbladder problems. Mounjaro USK is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Your UK prescriber will screen for these contraindications during your clinical assessment.

Managing Mounjaro USK Side Effects in Daily Life

UK patients using Mounjaro USK can employ several practical strategies to minimise side effects. Start with smaller portion sizes at meals, chew food thoroughly, and avoid lying down immediately after eating to reduce nausea and reflux. Ginger tea, peppermint, and acupressure wristbands may provide additional relief for gastrointestinal symptoms. If constipation occurs, increase your dietary fibre intake gradually, drink plenty of water, and consider a gentle over-the-counter laxative after consulting your pharmacist. Keeping a symptom diary helps identify triggers and allows your prescriber to tailor your treatment plan for optimal tolerability.

Mounjaro USK Pricing and How to Buy Online in the UK

Mounjaro USK is available at Cured Pharmacy from £124.99 per prescription, with transparent pricing displayed before you complete your clinical assessment. We offer the lowest prices guaranteed in the UK, with no hidden fees or surprise charges. New patients receive £20 off their first order using code Weightlossnew, making your initial prescription even more affordable.

To purchase Mounjaro USK online, complete our free 3-minute clinical questionnaire, which covers your medical history, current medications, weight management goals, and any contraindications. Our UK-registered prescribers review your assessment within hours, and if approved, your prescription is dispensed by our GPhC-registered pharmacy team. We source only genuine, UK-licensed Mounjaro directly from authorised wholesalers, ensuring medication authenticity and safety.

Delivery is fast and discreet, with most orders arriving within 1-2 working days via tracked courier. All packaging is plain and unmarked to protect your privacy. If you have questions about Mounjaro USK pricing, dosing, or suitability, our pharmacist-led support team is available by phone at (+44) 116 4646009 or via our online contact form.

Clinical Evidence Behind Mounjaro USK for Weight Loss in the UK

The approval of Mounjaro USK in the UK was based on robust clinical trial data from the SURMOUNT programme, which enrolled over 5,000 adults with obesity or overweight with weight-related comorbidities. SURMOUNT-1, the pivotal phase 3 trial, demonstrated that participants receiving tirzepatide 15mg lost an average of 20.9% of their baseline body weight over 72 weeks, compared to just 3.1% in the placebo group[2].

Importantly, 91% of Mounjaro USK participants in the 15mg group achieved at least 5% weight loss (a clinically meaningful threshold), while 57% achieved at least 20% weight loss—outcomes rarely seen with lifestyle interventions alone[2]. These results positioned tirzepatide as one of the most effective obesity medications currently available to UK patients, subject to prescriber approval and clinical suitability.

Beyond weight reduction, Mounjaro USK demonstrated favourable effects on cardiometabolic risk factors. Trial participants experienced significant improvements in HbA1c, fasting glucose, blood pressure, and lipid profiles[3]. These secondary benefits are particularly relevant for UK patients with obesity-related conditions such as prediabetes, hypertension, or dyslipidaemia. However, Mounjaro is not a cure for obesity—it works best when combined with a reduced-calorie diet and increased physical activity as part of a comprehensive weight management programme.

How Mounjaro USK Compares to Other UK Weight Loss Treatments

When comparing Mounjaro USK to other licensed weight loss medications in the UK, tirzepatide's dual-agonist mechanism offers distinct advantages. While Wegovy (semaglutide) activates only GLP-1 receptors and produced an average 14.9% weight loss in the STEP 1 trial, Mounjaro's additional GIP receptor activation may enhance weight reduction and metabolic benefits[2]. Saxenda (liraglutide), a daily injection, showed more modest weight loss of approximately 8% in clinical trials. Oral options like Orlistat work via fat malabsorption rather than appetite regulation, typically resulting in 5-10% weight loss but with different side effect profiles. Your UK prescriber will recommend the most appropriate treatment based on your individual clinical profile, preferences, and treatment goals.

Who Can Use Mounjaro USK in the UK and Eligibility Criteria

Mounjaro USK is licensed in the UK for adults aged 18 and over with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater in the presence of at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidaemia, or obstructive sleep apnoea[1]. These criteria align with NICE guidelines for pharmacological obesity treatment and ensure appropriate patient selection.

Certain medical conditions and patient characteristics may preclude Mounjaro USK use. Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastrointestinal disease, diabetic ketoacidosis, and hypersensitivity to tirzepatide or any excipients. Mounjaro is not recommended during pregnancy or breastfeeding, and women of childbearing potential should use effective contraception during treatment. Your UK prescriber will conduct a thorough assessment to identify any contraindications before issuing a prescription.

If you're currently taking other medications for diabetes or weight management, inform your prescriber during your Mounjaro USK assessment. Tirzepatide can interact with insulin and sulfonylureas, increasing the risk of hypoglycaemia, and may affect the absorption of oral medications due to delayed gastric emptying. Dose adjustments or alternative treatments may be necessary to ensure safe, effective therapy tailored to your unique clinical circumstances.

Mounjaro USK and Lifestyle Modifications for Optimal Results

While Mounjaro USK is highly effective for weight loss, it is not a standalone solution. UK prescribers emphasise the importance of combining medication with sustainable lifestyle changes, including a reduced-calorie diet and regular physical activity. Aim for a 500-750 calorie daily deficit through portion control and nutrient-dense food choices, and incorporate at least 150 minutes of moderate-intensity aerobic exercise per week, such as brisk walking, cycling, or swimming[4]. Behavioural support, whether through NHS weight management programmes, commercial services, or self-directed strategies, enhances long-term adherence and weight maintenance. Your Cured Pharmacy clinical team can provide guidance on integrating these lifestyle modifications with your Mounjaro USK prescription for optimal, sustained outcomes.

Scientific References

1. Electronic Medicines Compendium. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen - Summary of Product Characteristics. Medicines.org.uk. [accessed 1 October 2026]
2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., ... & Garvey, W. T. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 1 October 2026]
3. Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., ... & SURPASS-2 Investigators. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515. [accessed 1 October 2026]
4. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management. NICE Clinical Guideline [CG189]. [accessed 1 October 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 1 October 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 1 October 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 1 October 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.